Press Releases
Astrazeneca’s Imfinzi for unresectable Stage III non-small cell lung cancer gets FDA approval
AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the US FDA has approved Imfinzi for the treatment of patients...
Industry Reports
Merck signs its acquisition agreement with Viralytics to Increase its Leading Immuno-Oncolgy Pipeline
Merck , known as MSD outside the USA and Canada, and Viralytics Limited announced that the companies have signed a definitive agreement under which...
News
Envigo appoints Lynn Lewis as Senior Vice President of Global Sales
Envigo, a leading provider of nonclinical contract research services and research models, announced the appointment of Lynn Lewis to the position of Senior Vice...
Clinical Trials
Medigene receives approvals for its first clinical trial with TCR therapy MDG1011
Medigene AG announced that the German Senior Federal Authority "Paul-Ehrlich-Institute" (PEI) and the relevant ethics committee have approved the study design of the first...
Press Releases
Allergan Presents Data at the 2018 American Academy of Dermatology (AAD) Annual Meeting in San Diego
The meeting will be held at the San Diego Convention Center and the scheduled times (noted in local Pacific Time) for the Allergan presentations,...
Clinical Trials
Vertex announces positive results of phase 2 study of Nav1.8 inhibitor VX -150 for Acute pain
Vertex Pharmaceuticals Inc announced positive results of a Phase 2 study of the NaV1.8 inhibitor VX-150 in patients with acute pain following bunionectomy surgery....
Clinical Trials
OTEZLA® (Apremilast) Phase II Data Showed Clinically significant Improvements in Patients with Active Ulcerative Colitis
Celgene Corporation announced that data from a randomized, placebo-controlled, multi-center, phase II clinical trial of apremilast in patients with active ulcerative colitis who had...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read